NEWS
Beyond the signature: Building AI assurance into MLR workflows
Part 2/2: If AI does more of the review, what does the human need to see?
By Marina Hickson, Vivanti Europe, and Shazad Jafri, ABPI...
Touch-free review, or a signature on the algorithm?
Part 1 of 2: What AI-enabled MLR means for the medical signatory
By Shazad Jafri, ABPI Medical Signatory and Founder, SignAffairs, and Vivanti Europe
This summer,...
Biotechnology
AI Can’t Create What It Doesn’t Know: Why Inputs Matter
AI can analyse evidence faster than ever, but primary research with customers still creates the evidence pharmaceutical companies require for strategic decision making, says...
The biggest barrier to AI in life sciences isn’t the AI
Only 12% of agentic AI initiatives reached production over the past year. The challenge isn’t the technology, but ensuring AI can operate within highly...
Drug Discovery
Are animal models limiting progress in product development?
Toxicity Testing in the 21st Century (TT21C) is helping to reshape biological testing by focusing on the mechanisms that drive toxicity and disease.
Matt Stevenson,...
Turbocharging ‘good’ viruses to destroy bacteria
Scientists at the University of Leicester have developed a new technique that will turbocharge the use of phages for medicinal purposes.
The pioneering technique uses...
